Blood-brain barrier dysfunction and folate and vitamin B12 levels in first-episode schizophrenia-spectrum psychosis: a retrospective chart review.

"Declarations Conflict of interestM. Campana, L. Löhrs, J. Strauß, S. Münz, P. Fernando, T. Oviedo-Salcedo, I. Maurus, F. Raabe, J. Moussiopoulou and P. Eichhorn report no conflicts of interest. E. Wagner has been invited to Recordati advisory board meetings. P. Falkai was honorary speaker for Janssen-Cilag, Astra-Zeneca, Eli Lilly, Bristol Myers-Squibb, Lundbeck, Pfizer, Bayer Vital, SmithKline Beecham, Wyeth, and Essex. During the last 5 years, but not presently, he was a member of the advisory boards of Janssen, AstraZeneca, Eli Lilly, and Lundbeck. A. Hasan has been invited to scientific meetings by Lundbeck, Janssen-Cilag, and Pfizer, and he received paid speakerships from Janssen, Recordati, Otsuka and Lundbeck. He was a member of Roche, Otsuka, Lundbeck, Rovi, Recordati and Janssen advisory boards. Ethical approval and consent to participateThis retrospective study was approved by the university ethics committee (registration number: 18–570). Conflict of interest M. Campana, L. Löhrs, J. Strauß, S. Münz, P. Fernando, T. Oviedo-Salcedo, I. Maurus, F. Raabe, J. Moussiopoulou and P. Eichhorn report no conflicts of interest. E. Wagner has been invited to Recordati advisory board meetings. P. Falkai was honorary speaker for Janssen-Cilag, Astra-Zeneca, Eli Lilly, Bristol Myers-Squibb, Lundbeck, Pfizer, Bayer Vital, SmithKline Beecham, Wyeth, and Essex. During the last 5 years, but not presently, he was a member of the advisory boards of Janssen, AstraZeneca, Eli Lilly, and Lundbeck. A. Hasan has been invited to scientific meetings by Lundbeck, Janssen-Cilag, and Pfizer, and he received paid speakerships from Janssen, Recordati, Otsuka and Lundbeck. He was a member of Roche, Otsuka, Lundbeck, Rovi, Recordati and Janssen advisory boards."

"Funding Open Access funding enabled and organized by Projekt DEAL. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors."